Eliquis(apixaban)
Eliquis (apixaban) is a small molecule pharmaceutical. Apixaban was first approved as Eliquis on 2011-05-18. It is used to treat pulmonary embolism and venous thrombosis in the USA. It has been approved in Europe to treat arthroplasty, stroke, and venous thromboembolism. The pharmaceutical is active against coagulation factor X.
Download report
Favorite
COVID-19
BMS
Top 200 Pharmaceuticals by Retail Sales
Commercial
Trade Name
FDA
EMA
Eliquis (generic drugs available since 2020-07-28)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Apixaban
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ELIQUIS | Bristol Myers Squibb | N-202155 RX | 2012-12-28 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| eliquis | New Drug Application | 2023-05-12 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pulmonary embolism | EFO_0003827 | D011655 | I26 |
| venous thrombosis | HP_0004936 | D020246 | I82.40 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
241 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 1 | 9 | 12 | 14 | 31 | 66 |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | 5 | 9 | 5 | 11 | 11 | 39 |
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | — | 3 | 15 | 6 | 5 | 27 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | 3 | 2 | 9 | 3 | 4 | 20 |
| Thrombosis | D013927 | 3 | 3 | — | 4 | 2 | 12 | ||
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | 5 | 2 | 3 | 10 |
| Neoplasms | D009369 | C80 | — | 2 | 2 | 2 | 4 | 10 | |
| Covid-19 | D000086382 | U07.1 | — | 1 | 3 | 2 | 1 | 7 | |
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | 1 | — | 1 | 3 | 6 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | 1 | 1 | 2 | 1 | 6 |
Show 18 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ischemic stroke | D000083242 | 1 | 1 | 3 | — | 4 | 8 | ||
| Cerebral hemorrhage | D002543 | — | 1 | 4 | — | — | 5 | ||
| Aortic valve stenosis | D001024 | EFO_0000266 | Q25.1 | — | — | 3 | — | — | 3 |
| Transient ischemic attack | D002546 | EFO_0003764 | G45.9 | — | — | 1 | — | 1 | 2 |
| Chronic renal insufficiency | D051436 | N18 | 1 | — | 1 | — | — | 2 | |
| Atrial flutter | D001282 | EFO_0003911 | — | — | 2 | — | — | 2 | |
| Intracranial thrombosis | D020767 | — | — | 2 | — | — | 2 | ||
| Patent foramen ovale | D054092 | HP_0001655 | Q21.12 | — | 1 | 1 | — | — | 2 |
| Ischemia | D007511 | EFO_0000556 | — | — | 1 | — | — | 1 | |
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | 1 | — | — | 1 |
Show 17 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 7 | 2 | — | — | — | 9 | ||
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | 3 | 1 | — | — | — | 3 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | 2 | — | — | — | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 2 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | — | — | 1 | 2 | |
| Cerebrovascular disorders | D002561 | EFO_0003763 | I60-I69 | — | 1 | — | — | — | 1 |
| Takotsubo cardiomyopathy | D054549 | EFO_1002000 | I51.81 | — | 1 | — | — | — | 1 |
| Essential thrombocythemia | D013920 | D47.3 | — | 1 | — | — | — | 1 | |
| Polycythemia vera | D011087 | D45 | — | 1 | — | — | — | 1 | |
| Primary myelofibrosis | D055728 | D47.4 | — | 1 | — | — | — | 1 |
Show 11 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thromboembolism | D013923 | HP_0001907 | 1 | — | — | — | 2 | 3 | |
| Coagulation protein disorders | D020147 | 1 | — | — | — | 1 | 2 | ||
| Membranous glomerulonephritis | D015433 | EFO_0004254 | N03.2 | 1 | — | — | — | — | 1 |
| Peritoneal dialysis | D010530 | 1 | — | — | — | — | 1 | ||
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | 1 | — | — | — | — | 1 |
| Crohn disease | D003424 | EFO_0000384 | K50 | 1 | — | — | — | — | 1 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | 1 | — | — | — | — | 1 | |
| Proteinuria | D011507 | HP_0000093 | R80 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | — | 2 | 2 |
| Thrombophilia | D019851 | D68.59 | — | — | — | — | 1 | 1 | |
| Oral surgery | D013515 | — | — | — | — | 1 | 1 | ||
| Postoperative complications | D011183 | — | — | — | — | 1 | 1 | ||
| Oral surgical procedures | D019647 | — | — | — | — | 1 | 1 | ||
| Embolism | D004617 | — | — | — | — | 1 | 1 | ||
| Menorrhagia | D008595 | N92.0 | — | — | — | — | 1 | 1 | |
| Morbid obesity | D009767 | EFO_0001074 | — | — | — | — | 1 | 1 | |
| Periodontal diseases | D010510 | K05.6 | — | — | — | — | 1 | 1 | |
| Frailty | D000073496 | R53.1 | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | APIXABAN |
| INN | apixaban |
| Description | Apixaban is a pyrazolopyridine that is 7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide substituted at position 1 by a 4-methoxyphenyl group and at position 6 by a 4-(2-oxopiperidin-1-yl)phenyl group. It is used for the prevention and treatment of thromboembolic diseases. It has a role as an anticoagulant and an EC 3.4.21.6 (coagulation factor Xa) inhibitor. It is a pyrazolopyridine, a member of piperidones, a lactam and an aromatic ether. |
| Classification | Small molecule |
| Drug class | antithrombotics, blood coagulation factor XA inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1 |
Identifiers
| PDB | 2P16 |
| CAS-ID | 503612-47-3 |
| RxCUI | 1364430 |
| ChEMBL ID | CHEMBL231779 |
| ChEBI ID | 72296 |
| PubChem CID | 10182969 |
| DrugBank | DB06605 |
| UNII ID | 3Z9Y7UWC1J (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
Eliquis - Bristol Myers Squibb
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Eliquis - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13,513 documents
View more details
Safety
Black-box Warning
Black-box warning for: Eliquis
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,197 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more